Simplify Logo
Medtronic

Medtronic

Medical device maker advancing therapies

Account Manager 2 - Cathlab TAVI

Full-Time
No salary listed
Mid
Bachelor's, Associate's
Québec City, QC, Canada
Hybrid

Hybrid work includes responsibilities in both a clinical environment and a sales capacity.

About the job

Requirements
  • A high school diploma or equivalent and 6+ years of relevant experience, or an associate degree and 4+ years of relevant experience, or a bachelor's degree and 2+ years of relevant experience.
  • Relevant experience must be in sales, clinical work, or a related area within medical devices, medical technology, healthcare, or life sciences.
  • The employee must be independently mobile, interact with a computer, and communicate with peers and co-workers.
Responsibilities
  • Promote and sell Medtronic products and services within an assigned geographic area and/or specific customer accounts to meet or exceed sales targets.
  • Develop, build, and strengthen long-term relationships with stakeholders, including distributors and healthcare professionals.
  • Pursue leads, assess needs, and provide product services to maximize the benefits derived from Medtronic products and services.
  • Promote and establish education on the company's products and services.
  • Conduct market research, including research on customer and competitor activities.
  • Implement market development plans and strategies and make changes as needed.
  • Communicate customer feedback on new products and modifications to existing products or applications to internal stakeholders, including research and development, operations, and marketing.
  • Work in both a clinical environment and a sales capacity.
  • Manage multiple small- to mid-size accounts and identify new and potential customers.
  • Work independently with general supervision.
  • Work with sales, marketing, and finance to structure complex contracts.
  • Recommend enhancements to sales processes and changes in account tactics to solve problems, improve effectiveness, and achieve sales goals.
  • Communicate with external customers and vendors through negotiation and presentations to manage relationships and close sales.

About the company

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Get referred to Medtronic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 1, 2026 revenue rose 13.7%; Medtronic raised fiscal 2027 guidance.
  • Cornerstone Robotics partnership on September 1, 2026 expands Medtronic's robotics reach outside the U.S.
  • Pi-Cardia investment and PulseSelect India launch deepen structural heart and atrial fibrillation growth.

What critics are saying

  • A Boston jury ordered Medtronic to pay $88 million on August 4, 2026.
  • About 10,350 hernia mesh plaintiffs threaten years of Covidien litigation and payout leakage.
  • Neuromodulation softness and structural heart lag expose Medtronic if ablation growth normalizes in 2027.

What makes Medtronic unique

  • Hugo RAS gained U.S. FDA clearance for LigaSure RAS Maryland on September 16, 2026.
  • Medtronic paired cardiac, surgical, and monitoring assets across global procedures in one platform.
  • PulseSelect and Affera give Medtronic multiple electrophysiology tools against single-product competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Sep 16th, 2026
Medtronic's LigaSure vessel-sealing tech gets FDA clearance for Hugo robotic surgery system

Medtronic has received FDA clearance for its LigaSure RAS Maryland jaw device on the Hugo robotic-assisted surgery system. The vessel-sealing technology, previously used in over 45 million procedures globally, is now available for robotic-assisted surgery in the US. The instrument seals and cuts vessels up to 7mm in diameter in approximately 2 seconds whilst minimising thermal spread. It works exclusively with the Valleylab FT10 energy platform on the Hugo RAS system. The Hugo RAS system is currently cleared for urologic procedures in the US and is being used in multiple health systems. Medtronic is working to expand its indications to general and gynaecologic procedures. Outside the US, the system has been used in over 50 different surgical procedures across more than 35 countries. The LigaSure RAS Maryland instrument received CE Mark for European use in 2025.

PR Newswire APAC
Sep 15th, 2026
AmChamSG honors impact, innovation and leadership at the 2026 #AmChamREPRESENT Awards with mr. Heng Swee Keat, Former Deputy Prime Minister of Singapore and Chairman of the National Research Founda...

AmChamSG honors impact, innovation and leadership at the 2026 #AmChamREPRESENT Awards with mr. Heng Swee Keat, Former Deputy Prime Minister of Singapore and Chairman of the National Research Foundation, Singapore. 2026-09-15 22:19 1325 Medtronic and Junior Achievement take top honors in inaugural US250 Corporate Excellence Award as AmChamSG recognizes 22 companies and business leaders SINGAPORE, Sept. 15, 2026 /PRNewswire/ - The American Chamber of Commerce in Singapore (AmChamSG) recognized 22 companies and business leaders for excellence in innovation, leadership, workplace culture and U.S.-Singapore business ties at the 2026 #AmChamREPRESENT Awards dinner on September 8, 2026. Mr. Heng Swee Keat, Chairman of the National Research Foundation, Singapore and Former Deputy Prime Minister of Singapore, presented the awards. Mr. Heng Swee Keat, Former Deputy Prime Minister of Singapore and Chairman of the National Research Foundation, Singapore; Mr. Adam Click, AmChamSG Chairman and Regional Client Lead, Global Business Organization, Google Asia Pacific; Dr. Hsien-Hsien Lei, AmChamSG CEO; and the judges and recipients of the US250 Corporate Excellence award (photos of other award recipients appended) The six award categories recognize organizational excellence and individual leadership, spanning corporate excellence, digital and AI adoption, workplace culture, leadership development and contributions to U.S.-Singapore business ties. The awards were presented as part of the 2026 AmChamSG Regional Economic Conference, a two-day gathering of government, business and policy leaders examining the forces reshaping growth, resilience and competitiveness in Singapore and the region. Among this year's standout recipients, Medtronic received both the US250 Corporate Excellence Award and Empowering Workplace Award in the MNC category, while Micron was recognized for its leadership in AI adoption and received an Honorable Mention for US250 Corporate Excellence, together with The Lubrizol Corporation. Junior Achievement took the US250 Corporate Excellence Award in the SME & Others category. "Medtronic is proud to receive both the US250 Corporate Excellence Award and the Empowering Workplace Award, reflecting our commitment to responsible leadership, innovation, and meaningful impact across Southeast Asia. This recognition belongs to our people and the inclusive culture that enables them to thrive. We greatly value our longstanding partnership with AmCham and our shared commitment to advancing healthcare access, innovation, and regional progress," said Feng Dong, Vice President of Medtronic Asia. Introduced this year to commemorate the 250th anniversary of American independence, the US250 Corporate Excellence Award recognizes companies that embody the values of American enterprise - including boldness, resilience, openness and corporate responsibility - through the way they do business and contribute to society. The award highlights organizations that pair innovation and resilience with meaningful economic and community impact. In congratulating the recipients, AmChamSG CEO Dr. Hsien-Hsien Lei said, "Recognition matters because it acknowledges the effort and impact behind what has already been achieved. But the best awards should also inspire what comes next." "Through the #AmChamREPRESENT Awards, we want to celebrate companies and leaders who are making a difference today, while encouraging our business community to keep pushing forward, raising the bar and creating even greater impact. That spirit is especially meaningful as the United States marks 250 years of independence. The inaugural US250 Corporate Excellence Award recognizes the contributions American businesses have already made in Singapore and the region, while also challenging us to build on that legacy through continued innovation, resilience and partnership." * US250 Corporate Excellence Award - recognizes companies that demonstrate boldness, resilience, openness and corporate responsibility through their business operations and societal impact. * Quantum Leap in Digital & AI Award - recognizes excellence in using digital technologies and AI to create and enhance business value, including stronger customer experiences, productivity and decision-making. * Empowering Workplace Award - recognizes companies that prioritize employee engagement, personal growth, inclusive workplace practices and learning and development. * Anchor Leadership Award - recognizes individuals who have demonstrated strong, adaptable and people-centered leadership, particularly in guiding organizations through challenging periods. * Emerging Leader Award - recognizes individuals demonstrating the leadership skills, cross-functional capabilities and resilience required to excel as future organizational leaders. * U.S.-SG Business Builder Award - recognizes individuals who actively advance U.S.-Singapore business ties through trade and investment, advocacy, networks and cross-border collaboration. About AmCham Singapore Established in 1973, the American Chamber of Commerce in Singapore (AmChamSG) is the largest and the most active international business association in Singapore and Southeast Asia, with over 600 American and other global companies with significant U.S. business interests. AmChamSG is an independent, non-partisan business organization with the goal of offering insights and facilitating access and connections that provide members with a comprehensive understanding of the local, regional, and global operating environments. Its mission - to create value for its members by providing advocacy, community, and thought leadership. Visit: www.amcham.com.sg 2026 #AmChamREPRESENT Award Recipients | US250 Corporate Excellence Award | | MNC Category | Medtronic | | SME & Others Category | Junior Achievement | | Honorable Mention | Lubrizol | | Micron | | AI Advantage in Business Award | | MNC Category | Micron | | SME & Others Category | Aays | | Honorable Mention | Allen & Gledhill | | DocDoc | | Procter & Gamble | | Empowering Workplace Award | | MNC Category | Medtronic | | SME & Others Category | The Caffeine Experience | | Honorable Mention | Marsh | | Marina Bay Sands | | Anchor Leadership Award | | MNC Category | Vidmay Naini, General Manager, Global Emerging Markets, eBay | | SME & Others Category | Cole Anthony Sirucek, CEO, DocDoc | | Honorable Mention | Simon Kahn, Chief Marketing Officer, Google Asia Pacific | | Emerging Leader Award | | MNC Category | Alyssa Wee, Marketing Manager and Market Access, Vantive | | SME & Others Category | Dr. Anindita Santosa, CEO, AIGP | | Honorable Mention | Edwin Chuah, Business Development Director, Bitdeer | | Regional Business Catalyst | | MNC Category | Gabriel Tan, CEO, GUAVA International | | SME & Others Category | Dr. Sue-Anne Toh, CEO/Co-Founder, NOVI Health | | Honorable Mention | Hau Yee Ng, Founder & Executive Director, Junior Achievement |

Yahoo Finance
Sep 15th, 2026
Medtronic and Sonus partner on AI ultrasound patch to screen pregnant women for preeclampsia in Kenya

Sonus Microsystems has partnered with Medtronic to integrate its AI-powered wearable ultrasound platform with Medtronic's vital-sign monitoring technology. The collaboration, funded by the Gates Foundation, will evaluate the combined system in field studies in Kenya. The partnership aims to develop a non-invasive monitoring system for screening and triaging pregnant women at risk of early-onset preeclampsia. The studies will be coordinated with Kenyatta University and antenatal facilities in Nairobi. Preeclampsia affects approximately 8% of pregnancies globally and is a major cause of maternal and fetal mortality in low- and middle-income countries. The condition is characterised by high blood pressure and organ damage, yet current screening relies primarily on blood pressure measurement alone. The Sonus Patch makes ultrasound autonomous, enabling delivery in settings without specialised sonographers.

Yahoo Finance
Sep 10th, 2026
Medtronic surges 13.7% on growth boost, preps diabetes unit exit

Jim Cramer described Medtronic as a "quandary" on Mad Money, noting the medical device company delivered strong growth but its stock price remains unchanged since reporting. Medtronic posted fiscal first-quarter revenue of nearly $9.8 billion, up 13.7% organically, whilst non-GAAP diluted earnings per share rose 15.1% to $1.45. The company raised its full-year organic revenue growth forecast to 7.25%-7.75% from 6.75%-7.25%. Cardiovascular revenue increased 18.9% organically to $3.927 billion, with Cardiac Ablation Solutions up 88%. Medtronic plans to separate its diabetes division by year-end. Cramer expressed concern about diabetes divisions amid rising GLP-1 treatments. The first quarter included an extra fiscal week contributing approximately $570 million to growth.

Insider Monkey
Sep 10th, 2026
Medtronic's (MDT) heart devices are suddenly outgrowing the rest of med-tech.

Medtronic's (MDT) heart devices are suddenly outgrowing the rest of med-tech. Published September 9, 2026 at 10:18 pm EDT On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%. An extra selling week included in the quarter, which ended July 31, added roughly $570 million to that figure. Still, even stripping that out, management called it the strongest quarter in nearly eight years. The company used the beat to raise its full-year outlook. A heart business on fire. Cardiovascular revenue jumped 18.9% organically to $3.9 billion, and the standout inside it was Cardiac Ablation Solutions, which grew 88% worldwide. That business crossed $2 billion in trailing twelve-month revenue this quarter, a milestone Medtronic said it hit ahead of schedule, while its Sphere-9 catheter added nine points of US market share in the pulsed field ablation market. Cardiac Rhythm Management, one of the company's oldest and largest franchises at more than $5.5 billion a year, still grew 15% globally, powered by double-digit growth in the decade-old Micra pacemaker line. Cranial & Spinal Technologies grew 13%, helped by the AiBLE surgical ecosystem and the newly launched Stealth AXiS navigation platform. Diabetes revenue rose 14.9% to $843 million, and Pelvic Health grew 15% as procedures for the Altaviva system doubled sequentially. Robotics is scaling too: the US installed base for the Affera mapping system grew 35% sequentially, and Medtronic expects its Hugo surgical robot to pass 50,000 completed procedures by the end of the fiscal year, with procedure growth running at more than twice the market rate. Management backed all of this with a raise to fiscal 2027 organic revenue guidance, now 7.25% to 7.75%, and adjusted earnings per share guidance of $5.94 to $6.00, while adjusted operating margin expanded to 23.7%. Where the growth story cools. Not every part of the portfolio is firing. Neuromodulation grew just 3% globally, weighed down by ongoing softness in the spinal cord stimulation market and replacement headwinds in deep brain stimulation, a pocket of the business that has lagged for a while. Structural Heart, part of the interventional cardiology unit, grew only in the low single digits, a much slower pace than the rest of cardiovascular. Management also flagged a $50 million to $150 million foreign exchange headwind for the full fiscal year based on recent currency rates. Some of the current strength comes at a cost. SG&A expense rose 14% year over year to 32.4% of revenue as Medtronic integrates recent acquisitions and commercializes newer platforms, and gross margin absorbed a 50 basis point hit from unfavorable mix, largely tied to diabetes and the capital-heavy ablation business. Executives also said Cardiac Ablation Solutions growth, while still expected to outpace the market by more than three times next quarter, will moderate over the rest of the year as comparisons get tougher, and acute care and monitoring growth is expected to normalize as fiscal 2027 progresses. What the market is pricing in. Hedge fund ownership of Medtronic climbed from 60 funds in the prior quarter to 67 in the most recent one, pointing to building institutional conviction. Short interest sits at just 1.12% of the float, suggesting little organized skepticism toward the stock. Shares trade at a forward price-to-earnings ratio of 15.46 as of September 9, a modest multiple given the growth rates coming out of ablation and robotics. The real question for investors. Medtronic's quarter makes clear that its newest growth engines, cardiac ablation, robotic surgery and pelvic health, are scaling fast enough to offset the drag from slower units like neuromodulation and structural heart. The extra selling week flattered the headline number, but management's own math suggests underlying demand was still unusually strong. For the growth story to keep holding, Cardiac Ablation Solutions and Hugo need to keep expanding even as comparisons get harder and currency swings work against the company.